Burning Rock Biotech (BNR) Cash & Current Investments (2019 - 2026)

Burning Rock Biotech's Cash & Current Investments history runs 8 years deep, the most recent figure standing at $70.1 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 2.95% year-over-year to $70.1 million; the TTM figure through Mar 2026 stood at $70.1 million (down 2.95% YoY), while the FY2025 annual figure was $67.8 million, down 5.18% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $70.1 million, up from $67.8 million in the prior quarter.
• The five-year high for Cash & Current Investments was $228.4 million in Q1 2022, with the low at $65.6 million in Q3 2025.
• The 5-year median for Cash & Current Investments is $85.4 million (2023), against an average of $105.9 million.
• The sharpest annual moves came in 2022 and 2026: Cash & Current Investments tumbled 47.94% in 2022, then slipped 2.95% in 2026.
• Burning Rock Biotech's Cash & Current Investments stood at $130.1 million in 2022, then sank by 34.32% to $85.4 million in 2023, then dropped by 14.92% to $72.7 million in 2024, then dropped by 6.69% to $67.8 million in 2025, then grew by 3.4% to $70.1 million in 2026.
• Business Quant data shows BNR's Cash & Current Investments at $70.1 million in Q1 2026, $67.8 million in Q4 2025, and $65.6 million in Q3 2025.